Results 11 - 20 of 34 : Previous 1 2 3 4 Next
Can't Stop the Bleeding From a Paper Cut
ZymoGenetics' rThrombin product is delayed.
The Perfect Pharma Acquisition
What would it look like, exactly?
Novacea's (Statistically) Significant Change
The pharamceutical increases the number of subjects in its latest clinical trial.
The pharma's loss narrows for the quarter, and things should improve in the months to come.
Nektar signs a development deal for its lead drug.
The biotech company pulls its New Drug Application for Satraplatin.
After four phase 3 clinical trials, Advanced Magnetics is ready to submit a New Drug Application.
A doubling of earnings, but no jump in stock price?
ImClone announces a failed cancer study.
Sometimes, the Same Is Good Enough
Bristol-Myers Squibb's new drug doesn't work better, but it's easier to take.
Legal Information © 1995 - 2008 The Motley Fool. All rights reserved.
Market Data provided by 
Terms & Conditions
RSS Headlines
Fool UK